ECRONICON OPEN ACCESS

EC NEUROLOGY
Review Article

Exploring the Clinical Implications of Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies in Disease Pathogenesis

Ahed J Alkhatib[1,2,3]*

[1]*Department of Legal Medicine, Toxicology and Forensic Medicine, Jordan University of Science and Technology, Jordan*

[2]*International Mariinskaya Academy, Department of Medicine and Critical Care, Department of Philosophy, Academician Secretary of Department of Sociology, Jordan*

[3]*Cypress International Institute University, Texas, USA*

***Corresponding Author:** Ahed J Alkhatib, Department of Legal Medicine, Toxicology and Forensic Medicine, Jordan University of Science and Technology, Jordan.

Received: April 17, 2023; **Published:** May 22, 2023

Abstract

Myelin oligodendrocyte glycoprotein, also known as MOG, is a transmembrane protein that can be found in the central nervous system (CNS). It is extremely important for the process of myelination as well as the stability of axons. The primary purpose of this investigation was to carry out a review study on MOG from a variety of perspectives, and its findings have been presented here. Multiple sclerosis, neuromyelitis optica spectrum disorder, and acute disseminated encephalomyelitis are just some of the autoimmune diseases of the central nervous system that have been linked to the presence of MOG antibodies and MOG-specific T cells. These findings have been found in patients through a number of different research studies. It has been demonstrated that MOG antibodies can cause demyelination and inflammation in animal models, and the fact that these antibodies are present in some patients with the diseases in question suggests that they may play a pathogenic role. In addition, MOG-associated diseases appear to have significantly different clinical manifestations and responses to treatment compared to diseases that are not associated with MOG. These findings shed light on the significance of MOG antibody testing as an integral part of the diagnostic process for patients suspected of having autoimmune diseases affecting the central nervous system.

Keywords: *MOG; Central Nervous System; T Cells; Autoimmune Diseases; Myelin*

An overview of MOG

Myelin oligodendrocyte glycoprotein, also known as MOG, is a transmembrane protein that can be found in the central nervous system (CNS). It is extremely important for the process of myelination as well as the stability of axons. MOG is a glycoprotein that is expressed on the surface of myelin sheaths and oligodendrocytes, the cells in the central nervous system that are responsible for producing myelin. The involvement of MOG in a variety of neurological disorders, such as multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and acute disseminated encephalomyelitis (ADEM), has resulted in a significant increase in the amount of attention paid to this gene in recent years [1].

In the context of multiple sclerosis (MS), a chronic autoimmune disease that affects the central nervous system, MOG has been the subject of a significant amount of research (CNS). In multiple sclerosis (MS), the myelin sheath that surrounds nerve fibers is attacked by the immune system, which then causes a variety of neurological symptoms as a result. MOG has been identified as a key antigen in the pathogenesis of multiple sclerosis (MS), and MOG-specific T cells play an essential part in both the beginning and the progression of the disease [2].

In addition to multiple sclerosis (MS), the myelin oligodendrocyte glycoprotein (MOG) has been linked to a number of other neurological conditions, such as neuromyelitis optica spectrum disorder (NMOSD) and acute disseminated encephalomyelitis (ADEM) (ADEM). The presence of antibodies directed against MOG is the defining feature of the extremely uncommon autoimmune condition known as NMOSD, which primarily manifests in the optic nerves and spinal cord [3]. ADEM is a neurological condition that most commonly affects children. It is characterized by inflammation and demyelination in the central nervous system (CNS), and MOG antibodies have been implicated in the pathogenesis of the disease. ADEM is a neurological disorder that typically affects children [4].

The investigation of MOG has resulted in the creation of innovative diagnostic and therapeutic approaches for the aforementioned disorders. For instance, it has been demonstrated that the detection of MOG antibodies in the blood or cerebrospinal fluid is a useful diagnostic tool for differentiating NMOSD from other demyelinating disorders. Other demyelinating disorders include [5]. In addition, MOG-specific therapies, such as monoclonal antibodies that target MOG, are currently under development for the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) [6].

Oligodendrocytes, which are found in the central nervous system, are responsible for the production of MOG. It is expressed on the surface of oligodendrocytes as well as on the exterior lamella of myelin sheaths. Because it was demonstrated to be the target antigen in an animal model of MS known as experimental allergic encephalomyelitis [7], it has traditionally piqued the interest of researchers who are investigating multiple sclerosis (MS). On the other hand, MOG antibodies were shown to be non-specific in MS investigations [8]. Because of advancements in antibody detection methods using cell-based assays that detect MOG in its original structural state, MOG antibody has only recently emerged as a biomarker for CNS inflammatory demyelinating illnesses that are distinct from MS and NMOSD. This is due to the fact that improved antibody detection methods have made it possible. A recent study found that the most accurate and reliable tests for detecting MOG antibodies are those that use live cells expressing native full length human MOG. This is because some conformational epitopes are lost when MOG expressing cells are fixed, so these tests are the best option for detecting MOG antibodies [9]. Second, there is a widespread discovery of low positive samples, especially in healthy people, which necessitates additional research towards a suitable cutoff value for identifying clinically relevant results. In order to detect MOG-IgG, serum testing is recommended because the accuracy of CSF MOG-IgG testing is unknown. Oligoclonal bands are rarely identified in CSF, which demonstrates that the autoimmune process begins in the peripheral nervous system rather than in the central nervous system as is the case with multiple sclerosis (MS). There is a high incidence of prodromal symptoms prior to the beginning of MOG-antibody linked illness. These symptoms include fever, malaise, cough, and rhinorrhea [10]. The most common symptoms include optic neuritis, transverse myelitis, and acute disseminated encephalomyelitis (ADEM), which is most common in people under the age of 20 [11]. Involvement of the brain stem or the cerebellum may be indicated by symptoms such as ataxia, facial palsy, diplopia, or vertigo [32]. In addition, overlapping involvement of the central nervous system and the peripheral nervous system (acute inflammatory demyelinating neuropathy, myeloradiculitis, multifocal motor neuropathy, or brachial neuritis) was observed in a study not too long ago [12]. There is the possibility of a monophasic or recurrent clinical course. High titers and a persistent positive MOG-IgG response in ADEM are both associated with an increased risk of disease recurrence [13]. Optic neuritis can affect either eye, and it is typically accompanied by edema of the optic disc. This condition can affect either eye. An MRI scan might show amplification of the optic nerve, which would include the optic sheath as well. It is not uncommon to have enhancement of both the left and right anterior optic nerves that does not extend to the optic chiasm [14]. On MRI, the majority of people who have myelitis have

lesions that are longitudinally significant, and involvement of the conus is found more frequently in myelitis than in NMOSD. Lesions in the spinal cord typically affect the gray matter, which can be distinguished from lesions caused by MS and NMOSD by means of an MRI [15-17].

MOG structure and function

MOG (myelin oligodendrocyte glycoprotein) is a type I transmembrane protein that is predominantly expressed on the surface of oligodendrocytes, the myelin-producing cells of the central nervous system (CNS) [1]. It is also present on the surface of myelin sheaths, where it contributes to the maintenance of axonal stability and the proper functioning of the nervous system [18].

MOG consists of an extracellular domain, a transmembrane domain, and a cytoplasmic tail. The extracellular domain is the largest region of MOG and contains several immunoglobulin-like domains that are involved in protein-protein interactions. The transmembrane domain anchors MOG to the cell membrane, while the cytoplasmic tail is involved in intracellular signaling and protein trafficking [19].

The function of MOG is primarily related to myelin formation and maintenance. MOG is thought to play a key role in the compaction and stabilization of myelin sheaths by promoting the adhesion of adjacent myelin layers. It also participates in the regulation of ion channels, specifically those involved in calcium signaling, which are important for maintaining the proper function of neurons and glial cells [20].

In addition to its structural and regulatory functions, MOG is also a key antigen in several autoimmune disorders, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and acute disseminated encephalomyelitis (ADEM). In these disorders, the immune system recognizes MOG as a foreign antigen and mounts an attack against MOG-expressing cells, resulting in the destruction of myelin and the development of neurological symptoms [21].

In recent years, MOG has emerged as an important target for the development of novel diagnostic and therapeutic strategies for autoimmune disorders of the CNS. The detection of MOG antibodies in the blood or cerebrospinal fluid has proven to be a useful diagnostic tool for distinguishing between different demyelinating disorders, while MOG-specific therapies, such as monoclonal antibodies, are currently being developed for the treatment of MS, NMOSD, and ADEM [3].

MOG and multiple sclerosis (MS)

Demyelination, inflammation, and neurodegeneration are the hallmarks of multiple sclerosis (MS), a chronic autoimmune disease that affects the central nervous system (CNS). It is believed that people who are genetically predisposed to developing multiple sclerosis can have the disease triggered by an environmental factor, such as a viral infection [22]. Patients with multiple sclerosis have been found to have MOG-specific T cells in their blood as well as their cerebrospinal fluid (CSF). This has led researchers to believe that MOG plays a role in the development of the disease [23].

It is believed that MOG-specific T cells are responsible for the development of multiple sclerosis by recognizing and attacking MOG-expressing oligodendrocytes and myelin sheaths. This contributes to the destruction of these cells. It has been demonstrated that MOG-specific T cells are more prevalent in the CSF of MS patients than they are in the blood of these patients, suggesting that they may play a role in the development of MS lesions in the CNS. These findings were published in two separate studies [23,24].

In addition, MOG antibodies have been found in a subset of patients who have been diagnosed with MS. Because MOG antibodies have been shown to induce demyelination and inflammation in animal models, it is believed that they may in some instances be the cause of the disease [25]. However, the part that MOG antibodies play in the development of multiple sclerosis is still unknown and needs to be researched further [26].

MOG and neuromyelitis optica spectrum disorder

Rarely occurring neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system that primarily impacts the optic nerves and spinal cord. The presence of antibodies against the water channel protein aquaporin-4 (AQP4), which

is expressed on astrocytes in the central nervous system (CNS), is diagnostic of NMOSD [27]. Recent research, on the other hand, has shown that a portion of patients diagnosed with NMOSD also have MOG antibodies [28].

MOG-associated NMOSD is a separate clinical entity from AQP4-associated NMOSD. It has unique clinical characteristics and responds differently to treatment than AQP4-associated NMOSD. MOG-associated NMOSD is more common in children and adolescents, and is characterized by a higher incidence of optic neuritis and myelitis [1]. MOG-associated NMOSD also tends to have a more benign course than AQP4-associated NMOSD, with fewer relapses and less disability [26].

MOG and acute disseminated encephalomyelitis (ADEM)

ADEM is a rare autoimmune disease of the central nervous system that most commonly affects children. It is distinguished by widespread inflammation as well as demyelination of the brain and spinal cord. The presence of MOG antibodies has been demonstrated in a sizeable fraction of patients diagnosed with ADEM, with some studies reporting frequencies as high as forty percent [29,30].

There have been a number of clinical and radiological characteristics that have been linked to MOG antibody-positive ADEM. When compared to MOG antibody-negative ADEM, these include a higher frequency of cortical involvement, more extensive white matter involvement, and a greater likelihood of a multiphasic course [26,30,31]. In addition, having a positive MOG antibody test for ADEM has been linked to an increased risk of relapse in comparison to having a negative MOG antibody test for ADEM. Furthermore, some studies have suggested that having a positive MOG antibody test for ADEM may represent a separate clinical entity from having a negative MOG antibody test for ADEM [26,30].

In general, these findings point to the possibility that MOG antibodies play a part in the pathogenesis of ADEM. As a result, testing for MOG antibodies ought to be taken into consideration during the diagnostic workup of patients who may be suffering from ADEM.

Summary

Multiple sclerosis, neuromyelitis optica spectrum disorder, and acute disseminated encephalomyelitis are all conditions that have been linked, according to research, to the presence of MOG antibodies and MOG-specific T cells in a sizeable portion of the patients suffering from these conditions. It is believed that MOG antibodies and T cells are involved in the pathogenesis of these diseases. They do this by attacking oligodendrocytes and myelin sheaths in the central nervous system, which leads to demyelination and inflammation. MOG-associated diseases are distinguished from diseases that are not associated with MOG in both their clinical presentation and their responses to treatment. In the pathogenesis of these diseases, the role of MOG antibodies and T cells is still being investigated, and additional research is required to fully understand their contribution to the development and progression of disease.

Bibliography

1. Jarius S., *et al*. "MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin". *Journal of Neuroinflammation* 13.1 (2016): 279.

2. Weber MS., *et al*. "The role of antibodies in multiple sclerosis". *Biochimica et Biophysica Acta* 1812.2 (2011): 239-245.

3. Reindl M., *et al*. "MOG antibody-associated diseases". *Handbook of Clinical Neurology* 145 (2019): 325-342.

4. Rostásy K and Reindl M. "Role of myelin oligodendrocyte glycoprotein antibodies in pediatric neurology". *Seminars in Pediatric Neurology* 37 (2020): 100836.

5. Waters P., *et al*. "Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica". *Journal of Neurology, Neurosurgery, and Psychiatry* 87.9 (2016): 1005-1015.

6. Levin N and Chapman J. "Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic". *Current Treatment Options in Neurology* 23.9 (2021): 28.

7. Von Büdingen HC., *et al*. "Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination". *Journal of Clinical Immunology* 21 (2001): 155-170.

8. Karni A., *et al*. "Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis". *Archives of Neurology* 56 (1999): 311-315.

9. Reindl M., *et al*. "International multicenter examination of MOG antibody assays". *Neurology: Neuroimmunology and Neuroinflammation* 7 (2020): e674.

10. Flanagan EP. "Neuromyelitis optica spectrum disorder and other nonmultiple sclerosis central nervous system inflammatory diseases". *Continuum* 25 (2019): 815-844.

11. Jurynczyk M., *et al*. "Clinical presentation and prognosis in MOG-antibody disease: a UK study". *Brain* 140 (2017): 3128-3138.

12. Rinaldi S., *et al*. "Overlapping central and peripheral nervous system syndromes in MOGantibody associated disorders". *Neurology: Neuroimmunology and Neuroinflammation* 8 (2021): e924.

13. Lopez-Chiriboga AS., *et al*. "Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed criterion for MOG-IgG-associated disorders". *JAMA Neurology* 75 (2018): 1355-1363.

14. Chen J., *et al*. "Optic neuritis in the era of biomarkers". *Survey of Ophthalmology* 65 (2020): 12-17.

15. Dubey D., *et al*. "Clinical, radiographic and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody". *JAMA Neurology* 76 (2019): 301-309.

16. Alkhatib AJ. "Autoimmunity and Diseases". In: The Role of Microbes in Autoimmune Diseases. Springer, Singapore (2022).

17. Alkhatib AJ. "The Role of Microbes in Autoimmune Diseases". Springer, Singapore (2022).

18. Krishnamoorthy G., *et al*. "Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation". *Journal of Clinical Investigation* 128.4 (2018): 1357-1372.

19. Mader S., *et al*. "Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders". *Journal of Neuroinflammation* 8.1 (2011): 184.

20. Molnarfi N., *et al*. "MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies". *Journal of Experimental Medicine,* 210.13 (2013): 2921-2937.

21. Reich DS., *et al*. "Multiple sclerosis". *New England Journal of Medicine* 378.2 (2018): 169-180.

22. Ascherio A and Munger KL. "Environmental risk factors for multiple sclerosis. Part I: the role of infection". *Annals of Neurology* 77.4 (2015): 791-802.

23. Von Büdingen HC., *et al*. "B cells in multiple sclerosis: connecting the dots". *Current Opinion in Immunology* 24.6 (2012): 702- 709.

24. Linares D., *et al*. "T-cell epitopes in multiple sclerosis, type 1 diabetes and rheumatoid arthritis: A bioinformatics evaluation". *PLoS One* 14.10 (2019): e0223397.

25. Jurynczyk M., *et al*. "Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis". *Brain* 140.3 (2017): 617-627.

26. Hamid SHM., *et al*. "What proportion of patients with relapsing-remitting multiple sclerosis are misdiagnosed?" *European Journal of Neurology* 25.3 (2018): 524-530.

27. Wingerchuk DM., *et al*. "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders". *Neurology* 85.2 (2015): 177-189.

28. Jarius S and Wildemann B. "AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance". *Nature Reviews Neurology* 6.7 (2010): 383-392.

29. Baumann M., *et al*. "Clinical and radiological differences between MOG-and AQP4-mediated relapsing optic neuritis". *Frontiers in Neurology* 12 (2021): 711115.

30. Hacohen Y., *et al*. "Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort". *Journal of Neurology, Neurosurgery, and Psychiatry* 85.4 (2014): 456-461.

31. Baumann M., *et al*. "Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases". *Multiple Sclerosis Journal* 22.14 (2016): 1821-1829.

32. Banks SA., *et al*. "Brainstem and cerebellar involvement in MOG0IgG-associated disorder versus aquaporin-4-IgG and MS". *Journal of Neurology, Neurosurgery, and Psychiatry* (2020): 1-7.

Volume SP15 2023